• **Name:** **Yosuke Togashi**

• **Current Position & Affiliation:** **Division Head, Chiba Cancer Center, Research Institute**

• **Country:** **Japan**

• **Educational Background:**

2000-2006: School of Medicine, Kyoto University, M.D., Kyoto, Japan
2012-2015: Graduate School of Medicine, Kindai University, Ph.D., Osaka, Japan

• **Professional Experience:**

2011-2012: Assistant Professor, Department of Multidisciplinary Cancer Treatment, Graduate School of Medicine and Faculty of Medicine Kyoto University, Kyoto, Japan
2014-2015: Research Fellowship for Young Scientist, Japan Society for the Promotion of Science (DC2)
2015-2016: Assistant Professor, Department of Genome Biology, Kindai University, Osaka, Japan.
2016-2019: Researcher, Division of Cancer Immunology, National Cancer Center, Chiba, Japan
2017-2018: Research Fellowship for Young Scientist, Japan Society for the Promotion of Science (PD)
2019-present: Division Head, Chiba Cancer Center, Research Institute, Chiba, Japan

• **Professional Organizations:**

The Japanese Society of Internal Medicine; The Japanese Respiratory Society; The Japan Lung Cancer Society; The Japanese Cancer Association (JCA) (councilor); The Japanese Society of Medical Oncology (JSMO); The Japanese Society of Immunology; American Association for Cancer Research (AACR).

• **Main Scientific Publications:**

1. Kumagai S, **Togashi Y (corresponding author)**, Sakai S, et al. Metabolic advantage conferred by a driver gene alteration maintains Treg cell abundance and function in the tumor microenvironment. **Immunity** in press.
2. Sugiyama E, **Togashi Y (equally contribution),** Takeuchi Y, et al. Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non–small cell lung cancer. **Sci Immunol** 5: eaav3937, 2020.
3. Umemoto K, **Togashi Y (corresponding)**, Arai Y, et al. The potential application of PD-1 blockade therapy for early-stage biliary tract cancer. **Int Immunol** 32: 273-281, 2020.

4. Tanegashima T, **Togashi Y (corresponding)**, Azuma K, et al. Immune suppression by PD-L2 against spontaneous and treatment-related antitumor immunity. **Clin Cancer Res** 25: 4808-4819, 2019.
5. Kamada T, **Togashi Y (equally contribution),** Tay C, et al. PD-1^{+} regulatory T cells are activated by PD-1 blockade and contribute to hyperprogression of cancer. **Proc Natl Acad Sci USA** 116: 9999-10008, 2019.
6. **Togashi Y,** Shitara K, Nishikawa H. Treg cells in cancer immunosuppression - Implications for anticancer therapy. **Nat Rev Clin Oncol** 16: 356-371, 2019.
7. Tada Y, **Togashi Y (equally contribution)**, Kotani D, et al. Targeting VEGFR2 with Ramucirumab strongly impacts effector/activated regulatory T cells and CD8^{+} T cells in the tumor microenvironment. **J Immunother Cancer** 6 : 106, 2018.
8. **Togashi Y** and Nishikawa H. Suppression from beyond the grave. **Nat Immunol** 18: 1285-6, 2017.
9. Terashima M, **Togashi Y,** Sato K, et al. Functional analyses of mutations in receptor tyrosine kinase genes in non-small cell lung cancer: double-edged sword of DDR2. **Clin Cancer Res** 22: 3663-71, 2016.
10. **Togashi Y**, Mizuuchi H, Kobayashi Y, et al. An activating ALK gene mutation in ALK IHC-positive/FISH-negative non-small cell lung cancer. **Ann Oncol** 26: 1800-1, 2015.

KSMO 2020 Secretariat: P&M, 3F, MS B/D, 12, Eonju-ro 79-gil, Gangnam-gu, Seoul, Korea Tel: +82-2-557-8422, 8423 FAX: +82-2-557-8428 E-mail: info@ksmoconference.org